Literature DB >> 9479476

Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.

D J Peet1, D F Doyle, D R Corey, D J Mangelsdorf.   

Abstract

BACKGROUND: The retinoid X receptor (RXR) activates transcription of target genes in response to its natural ligand, 9-cis retinoic acid (9cRA), and a number of RXR-specific synthetic ligands. To discover the potential for engineering nuclear receptors for activation of transcription by novel ligands, we used structure-based mutagenesis to change the ligand specificity of RXR.
RESULTS: By making substitutions at only two positions (Phe313 and Leu436) we engineered two new classes of RXR proteins that had altered ligand specificities. The first class exhibits decreased activation by 9cRA and increased activation by synthetic ligands. The second class continues to be activated by 9cRA but no longer responds to synthetic ligands. The magnitude of the change in specificity that can be accomplished is greater than 280-fold.
CONCLUSIONS: These results confirm that Phe313 and Leu436 are crucial determinants of ligand specificity for RXR and demonstrate that nuclear receptors are exceptionally promising protein scaffolds for the introduction of novel ligand specificities through structure-based protein engineering.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479476     DOI: 10.1016/s1074-5521(98)90083-7

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  10 in total

1.  Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid.

Authors:  P F Egea; A Mitschler; N Rochel; M Ruff; P Chambon; D Moras
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

2.  Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.

Authors:  Yan Zhang; Marie-Hélène Larraufie; Leila Musavi; Hemanth Akkiraju; Lewis M Brown; Brent R Stockwell
Journal:  Biochemistry       Date:  2018-02-06       Impact factor: 3.162

3.  Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function.

Authors:  I G Schulman; G Shao; R A Heyman
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta.

Authors:  B A Janowski; M J Grogan; S A Jones; G B Wisely; S A Kliewer; E J Corey; D J Mangelsdorf
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

5.  Creation and discovery of ligand-receptor pairs for transcriptional control with small molecules.

Authors:  Lauren J Schwimmer; Priyanka Rohatgi; Bahareh Azizi; Katherine L Seley; Donald F Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

Review 6.  Retinoic acid actions through mammalian nuclear receptors.

Authors:  Pengxiang Huang; Vikas Chandra; Fraydoon Rastinejad
Journal:  Chem Rev       Date:  2013-12-05       Impact factor: 60.622

7.  Sulindac-derived RXRα modulators inhibit cancer cell growth by binding to a novel site.

Authors:  Liqun Chen; Zhi-Gang Wang; Alexander E Aleshin; Fan Chen; Jiebo Chen; Fuquan Jiang; Gulimiran Alitongbieke; Zhiping Zeng; Yue Ma; Mingfeng Huang; Hu Zhou; Gregory Cadwell; Jian-Feng Zheng; Pei-Qiang Huang; Robert C Liddington; Xiao-kun Zhang; Ying Su
Journal:  Chem Biol       Date:  2014-04-03

8.  Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα.

Authors:  Liqun Chen; Alexander E Aleshin; Gulimiran Alitongbieke; Yuqi Zhou; Xindao Zhang; Xiaohong Ye; Mengjie Hu; Gaoang Ren; Ziwen Chen; Yue Ma; Duo Zhang; Shuai Liu; Weiwei Gao; Lijun Cai; Lingjuan Wu; Zhiping Zeng; Fuquan Jiang; Jie Liu; Hu Zhou; Gregory Cadwell; Robert C Liddington; Ying Su; Xiao-Kun Zhang
Journal:  Nat Commun       Date:  2017-07-17       Impact factor: 14.919

Review 9.  Identification of an irreversible PPARγ antagonist with potent anticancer activity.

Authors:  Youyi Peng; Qiang Zhang; Robert M Zielinski; Richard D Howells; William J Welsh
Journal:  Pharmacol Res Perspect       Date:  2020-12

10.  Structural motifs recurring in different folds recognize the same ligand fragments.

Authors:  Gabriele Ausiello; Pier Federico Gherardini; Elena Gatti; Ottaviano Incani; Manuela Helmer-Citterich
Journal:  BMC Bioinformatics       Date:  2009-06-15       Impact factor: 3.169

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.